الفهرس 
Assessment of response to sofosbuvir-based triple therapy versus sofosbuvir-based dual therapy in chronic HCV treatment experienced patients
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 105 |  |  |
| | | from | 105 | | |
Abstract
Background: HCV is a major public health in Egypt carrying many complications. Treatment with pegylated interferon and ribavirin was associated with many contraindications and complications as well as modest sustained virological response (SVR). With the emergence of sofosbuvir based treatment regimens the SVR markedly improved even with treatment experienced (pegylated interferon/ribavirin) patients. Aim of the work: Assessment of the response ofsofosbuvir based dual therapy versussofosbuvir based triple therapy in pegylated interferon/ribavirin experienced patients. Patients and methodology: this study was conducted on 200 HCV treatment experienced patients divided into two groups; group (1): received dual therapy (SOF+RBV) for 24 weeks and group (2): received triple therapy (SOF+RBV+PEG-IFN) for 12 weeks. Both groups were compared regarding baseline characteristics, rapid virological response (RVR), end of treatment response (ETR) and SVR and side effects. Results: Males represented 65% of the studied population (p value 0.003), 14.5% were cirrhotic and 18% were diabetics. Significant DROP of serum transaminases level was reported in both groups during the treatment. Significant rise of bilirubin level and decline of hemoglobin were reported with ribavirin use in both groups. RVR (group (1) 95%, group (2) 99%) and ETR (group(1) 98%, group (2) 100%) were comparable in both groups. SVR was significantly higher in group (2)(triple therapy) 96% than group (1) (dual therapy) 79% with p value 0.001. Conclusion: SVR of triple therapy (SOF+RBV+PEG-IFN) for 12 weeks in chronic PEG-IFN and RBV experienced HCV patients is better than dual therapy (SOF+RBV) for 24weeks